We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest trading session, Moderna (MRNA - Free Report) closed at $188.94, marking a -1.89% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.2%. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, added 0.04%.
Shares of the biotechnology company have appreciated by 27.69% over the course of the past month, outperforming the Medical sector's loss of 1.75%, and the S&P 500's loss of 0.35%.
Analysts and investors alike will be keeping a close eye on the performance of Moderna in its upcoming earnings disclosure. On that day, Moderna is projected to report earnings of -$1.36 per share, which would represent a year-over-year decline of 166.67%. Our most recent consensus estimate is calling for quarterly revenue of $888.78 million, down 12.52% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$8.5 per share and revenue of $2.11 billion. These totals would mark changes of -17.08% and +8.31%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Moderna. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Moderna is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 182, putting it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
In the latest trading session, Moderna (MRNA - Free Report) closed at $188.94, marking a -1.89% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.2%. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, added 0.04%.
Shares of the biotechnology company have appreciated by 27.69% over the course of the past month, outperforming the Medical sector's loss of 1.75%, and the S&P 500's loss of 0.35%.
Analysts and investors alike will be keeping a close eye on the performance of Moderna in its upcoming earnings disclosure. On that day, Moderna is projected to report earnings of -$1.36 per share, which would represent a year-over-year decline of 166.67%. Our most recent consensus estimate is calling for quarterly revenue of $888.78 million, down 12.52% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$8.5 per share and revenue of $2.11 billion. These totals would mark changes of -17.08% and +8.31%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Moderna. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Moderna is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 182, putting it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.